Hiroki Sato

Dr. Hiroki Sato

Department of Medicine, Asahikawa Medical University, 2-1 Midorigaoka-Higashi, Asahikawa, Hokkaido 078-8510, Japan
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TGTakuma Goto
Takuma Goto
MFMikihiro Fujiya
Mikihiro Fujiya
HKHiroaki Konishi
Hiroaki Konishi
JSJunpei Sasajima
Junpei Sasajima
SFShugo Fujibayashi
Shugo Fujibayashi
TOToshikatsu Okumura
Toshikatsu Okumura
Pancreatic cancer is associated with an extremely poor prognosis, so new biomarkers that can detect the initial stages are urgently needed. The significance of serum microRNA (miR) levels in pancreatic neoplasm such as pancreatic cancer and intraductal papillary mucinous neoplasm (IPMN) diagnosis remains unclear. We herein evaluated the usefulness of miRs enclosed in serum exosomes (ExmiRs) as diagnostic markers. The ExmiRs from patients with pancreatic cancer (n = 32) or IPMN (n = 29), and patients without neoplasms (controls; n = 22) were enriched using ExoQuick-TC™. The expression of ExmiRs was evaluated using a next-generation sequencing analysis, and the selected three miRs through this analysis were confirmed by a quantitative real-time polymerase chain reaction. The expression of ExmiR-191, ExmiR-21 and ExmiR-451a was significantly up-regulated in patients with pancreatic cancer and IPMN compared to the controls (p < 0.05). A receiver operating characteristic curve analysis showed that the area under the curve and the diagnostic accuracy of ExmiRs were 5–20% superior to those of three serum bulky circulating miRs (e.g.; ExmiR-21: AUC 0.826, accuracy 80.8%. Circulating miR-21: AUC 0.653, accuracy 62.3%). In addition, high ExmiR-451a was associated with mural nodules in IPMN (p = 0.010), and high ExmiR-21 was identified as a candidate prognostic factor for the overall survival (p = 0.011, HR 4.071, median OS of high-ExmiR-21: 344 days, median OS of low-ExmiR-21: 846 days) and chemo-resistant markers (p = 0.022). The level of three ExmiRs can thus serve as early diagnostic and progression markers of pancreatic cancer and IPMN, and considered more useful markers than the circulating miRs (limited to these three miRs).

1 January 2016 in World Journal of Gastroenterology
Verified
Journal Article
Open access
MFMikihiro Fujiya
Mikihiro Fujiya
Hiroki SatoHiroki Sato
Hiroki Sato
NUNobuhiro Ueno
Nobuhiro Ueno
ASAki Sakatani
Aki Sakatani
KTKazuyuki Tanaka
Kazuyuki Tanaka
YKYutaka Kohgo
Yutaka Kohgo
AIM: To compare previously reported randomized controlled studies (RCTs) of cold and hot polypectomy, we systematically reviewed and clarify the utility of cold polypectomy over hot with respect to efficacy and adverse events. METHODS: A meta-analysis was conducted to evaluate the predominance of cold and hot polypectomy for removing colon polyps. Published articles and abstracts from worldwide conferences were searched using the keywords “cold polypectomy”. RCTs that compared either or both the effects or adverse events of cold polypectomy with those of hot polypectomy were collected. The patients’ demographics, endoscopic procedures, No. of examined lesions, lesion size, macroscopic and histologic findings, rates of incomplete resection, bleeding amount, perforation, and length of procedure were extracted from each study. A forest plot analysis was used to verify the relative strength of the effects and adverse events of each procedure. A funnel plot was generated to assess the possibility of publication bias. RESULTS: Ultimately, six RCTs were selected. No significant differences were noted in the average lesion size (less than 10 mm) between the cold and hot polypectomy groups in each study. Further, the rates of complete resection and adverse events, including delayed bleeding, did not differ markedly between cold and hot polypectomy. The average procedural time in the cold polypectomy group was significantly shorter than in the hot polypectomy group. CONCLUSION: Cold polypectomy is a time-saving procedure for removing small polyps with markedly similar curability and safety to hot polypectomy.

21 July 2022 in World Journal of Gastroenterology
Verified
Journal Article
Open access
BPBirte Purschke
Birte Purschke
LBLouisa Bolm
Louisa Bolm
MMMax Nikolaus Meyer
Max Nikolaus Meyer
Hiroki SatoHiroki Sato
Hiroki Sato
Interventional strategies in infected necrotizing pancreatitis: Indications, timing, and outcomes

27 January 2022 in Surgery Today
Verified
Journal Article
Closed access
PDF file
TMTakashi Matsumoto
Takashi Matsumoto
YKYuki Kitano
Yuki Kitano
KIKatsunori Imai
Katsunori Imai
SKShotaro Kinoshita
Shotaro Kinoshita
Hiroki SatoHiroki Sato
Hiroki Sato
HBHideo Baba
Hideo Baba

Verified
Journal Article
Open access
PDF file
HKHiroaki Konishi
Hiroaki Konishi
Hiroki SatoHiroki Sato
Hiroki Sato
KTKENJI TAKAHASHI
KENJI TAKAHASHI
MFMikihiro Fujiya
Mikihiro Fujiya
MicroRNAs (miRNAs) are single-stranded short-chain RNAs that are endogenously expressed in vertebrates; they are considered the fine-tuners of cellular protein expression that act by modifying mRNA translation. miRNAs control tissue development and differentiation, cell growth, and apoptosis in cancer and non-cancer cells. Aberrant regulation of miRNAs is involved in the pathogenesis of various diseases including cancer. Numerous investigations have shown that the changes in cellular miRNA expression in cancerous tissues and extracellular miRNAs enclosed in exosomes are correlated with cancer prognosis. Therefore, miRNAs can be used as cancer biomarkers and therapeutic targets for cancer in clinical applications. In the previous decade, miRNAs have been shown to regulate cellular functions by directly binding to proteins and mRNAs, thereby controlling cancer progression. This regulatory system implies that cancer-associated miRNAs can be applied as molecular-targeted therapy. This review discusses the roles of miRNA–protein systems in cancer progression and its future applications in cancer treatment.

1 August 2021 in Pancreatology
Verified
Journal Article
Closed access
Hiroki SatoHiroki Sato
Hiroki Sato
TGTakuma Goto
Takuma Goto
AHAkihiro Hayashi
Akihiro Hayashi
HKHidemasa Kawabata
Hidemasa Kawabata
TOTetsuhiro Okada
Tetsuhiro Okada
TOToshikatsu Okumura
Toshikatsu Okumura